ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- A scoping review on the community dividend resulting from testing and treating hepatitis C infection in people living in detention.Epidemiology and infection · 2024Article
- Advancing Hepatitis C Elimination through Opt-Out Universal Screening and Treatment in Carceral Settings, United States.Emerging infectious diseases · 2024Review
- Hepatitis C Virus Elimination in the United States: Challenges, Progress, and Future Steps.Gastroenterology & hepatology · 2023Article
- Racial differences in testing for infectious diseases: An analysis of jail intake data.PloS one · 2023Article
- Metamodeling for Policy Simulations with Multivariate Outcomes.Medical decision making : an international journal of the Society for Medical Decision Making · 2022Article
- Finding Cases of Hepatitis C for Treatment Using Automated Screening in the Emergency Department is Effective, but What Is the Cost?Canadian journal of gastroenterology & hepatology · 2022Article
- Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.The International journal on drug policy · 2021Article
- Innovations in Hepatitis C Screening and Treatment.Hepatology communications · 2021Review
- Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky.The International journal on drug policy · 2021Article
- Hepatitis C Virus Prevalence, Screening, and Treatment Among People Who Are Incarcerated in Canada: Leaving No One Behind in the Direct-Acting Antiviral Era.Clinical liver disease · 2021Review
- Article
- Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda.The Journal of infectious diseases · 2020Article
- Screening for Hepatitis C Virus: How Universal Is Universal?Clinical therapeutics · 2020Review
- Putting the Dissemination and Implementation in Infectious Diseases.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination.Current HIV/AIDS reports · 2020Review
- Modeling as Visioning: Exploring the Impact of Criminal Justice Reform on Health of Populations with Substance Use Disorders.MDM policy & practiceArticle
- A Decade of the National Center for HIV, Viral Hepatitis, STD, and TB Prevention's Epidemiologic and Economic Modeling Agreement.Public health reports (Washington, D.C. : 1974)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHepatitis C virus (HCV) testing and treatment uptake in prisons remains low. We aimed to estimate clinical outcomes, cost-effectiveness (CE), and budgetary impact (BI) of HCV testing and treatment in United States (US) prisons or linkage to care at release.
methodsWe used individual-based simulation modeling with healthcare and Department of Corrections (DOC) perspectives for CE and BI analyses, respectively. We simulated a US prison cohort at entry using published data and Washington State DOC individual-level data. We considered permutations of testing (risk factor based, routine at entry or at release, no testing), treatment (if liver fibrosis stage ≥F3, for all HCV infected or no treatment), and linkage to care (at release or no linkage). Outcomes included quality-adjusted life-years (QALY); cases identified, treated, and cured; cirrhosis cases avoided; incremental cost-effectiveness ratios; DOC costs (2016 US dollars); and BI (healthcare cost/prison entrant) to generalize to other states.
resultsCompared to "no testing, no treatment, and no linkage to care," the "test all, treat all, and linkage to care at release" model increased the lifetime sustained virologic response by 23%, reduced cirrhosis cases by 54% at a DOC annual additional cost of $1440 per prison entrant, and would be cost-effective. At current drug prices, targeted testing and liver fibrosis-based treatment provided worse outcomes at higher cost or worse outcomes at higher cost per QALY gained. In sensitivity analysis, fibrosis-based treatment restrictions were cost-effective at previous higher drug costs.
conclusionsAlthough costly, widespread testing and treatment in prisons is considered to be of good value at current drug prices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.